ImmunoPrecise Antibodies (IPA) has released an update.
ImmunoPrecise Antibodies subsidiary, BioStrand, has launched a new AI-driven software, LENSai API, aimed at revolutionizing the drug discovery process by integrating large datasets and electronic health records. The software promises to be easily adaptable for use in pharmaceutical, healthcare, and technology sectors, offering unprecedented research and drug development capabilities. This move is set to meet industry needs and is already attracting significant interest from major companies.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.
